ArticleBone research2026
Bone adhesive with temporally-synchronized degradation for enhanced osteointegration.
Article in Bone research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Bone adhesives have emerged as promising alternatives for complex fracture fixation. However, discrepancies between material degradation rates and the physiological timeline of bone healing remain a critical limitation. Here, a polyurethane-based adhesive (TNC) was developed, synthesized from trimeric hexamethylene diisocyanate, nano-hydroxyapatite, and type I collagen. The TNC demonstrates strong initial adhesion to both wet and blood-contaminated bone surfaces and exhibits excellent biocompatibility. A distinguishing feature of TNC is its capacity to synchronize degradation with the stages of bone healing. During degradation, TNC forms a mineralized surface layer that releases calcium ions. The calcium ions activate cathepsin K, an enzyme integral to bone remodeling. This calcium-mediated mechanism accelerates TNC degradation by 1.9-fold during the remodeling phase compared to the initial phase. In a rat skull fracture model, TNC supported effective fracture stabilization and achieved favorable bone regeneration at 8 weeks after implantation. These findings demonstrate that TNC combines early mechanical stability with phase-specific degradability to facilitate bone regeneration in a temporally-controlled manner. The present work provides a framework for the development of bio-responsive bone adhesives that synchronize degradation behavior with healing phases for orthopedic applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.